Análises dos estudos ACOSOG Z1031 e ShortHER avaliam terapia endócrina no câncer de mama

Notas do episódio

Referências: 1. Hunt, K.K., Suman, V.J., Wingate, H.F. et al. Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer. Ann Surg Oncol (2023). https://doi.org/10.1245/s10434-022-12972-5ou https://link.springer.com/article/10.1245/s10434-022-12972-5 2. Dieci, M.V., Bisagni, G., Bartolini, S. et al. Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. npj Breast Cancer 9, 6 (2023). https://doi.org/10.1038/s41523-023-00509-2ou https://www.nature.com/articles/s41523-023-00509-2 --